Role of immunosuppressive therapy for the treatment of multiple sclerosis - Wikidata - wikimedia - TriplyDB

Role of immunosuppressive therapy for the treatment of multiple sclerosis

Role of immunosuppressive therapy for the treatment of multiple sclerosis

http://www.wikidata.org/entity/Q26827467

about

Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Twenty-five years of progress: the view from NIMH and NINDS The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.The associations of thiopurines with male fertility and paternally exposed offspring: a systematic review and meta-analysis.Dendrimers: Breaking the paradigm of current musculoskeletal autoimmune therapies.Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis.Differentially expressed microRNA in multiple sclerosis: A window into pathogenesis?Zelldepletion und Myeloablation bei neuroimmunologischen Erkrankungen

P2860

Q30869048-2CDEAFAB-74C3-4404-8FAD-E51FC717FB86 Q33589947-969C0D0B-9DE4-48F7-A1CC-E646A27E1441 Q35910495-959A9D33-B586-4101-9AA6-AB0738F2FF6B Q36062456-B9731651-3206-435D-AEFB-DFC93FACEF58 Q37384323-635C3D26-55AD-430D-8529-48B49BF2E501 Q38761495-FD899747-80D2-4BD1-8344-74C0B567C15A Q39032639-A0310935-B985-4A40-9AE0-27547826987D Q47391247-19D4E57C-A19B-4D57-BF74-87700CA42C2A Q47429306-2B02F8F8-C391-4500-9218-C16B05B9E38B Q47901567-D08EA976-66F3-4DF1-81F5-4CDBFFA62AE3 Q56688688-79688621-BE5C-41D3-BC0B-E0525C56005E Q57912843-66B6092E-F54A-454E-B631-CC58B74F2CF0

P2860

Role of immunosuppressive therapy for the treatment of multiple sclerosis

http://www.wikidata.org/entity/Q26827467

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@ast

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@en

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@nl

type

label

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@ast

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@en

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@nl

prefLabel

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@ast

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@en

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@nl

P1433

Q26827467-8DB1EF76-7102-48D0-BA82-937F6EF0DDD8

P1476

Q26827467-888152A8-8BE6-442E-AE1E-EC1239003CD8

P2093

Q26827467-276AB609-7F84-4778-B712-C9C6BCE29AF2

Q26827467-4499DB2D-5229-4072-B5A0-C32ABDFA4E38

P2860

Q26827467-00133E22-1780-4FDD-AA49-C5233A30EBCF

Q26827467-05821A70-C783-4D4F-8869-074F46666E62

Q26827467-0872DD23-497C-4BE3-A07C-61ECA5BF11F0

Q26827467-0C5964E1-43B7-489E-8BEC-EF2B1FA965BE

Q26827467-159F3AC5-10C4-46E6-9B5A-FC9875935F1A

Q26827467-169BFB5D-4E9D-4104-8279-2E8E636AE60D

Q26827467-1CBB2907-7D67-43C2-A6CD-352BAE5A20AA

Q26827467-1DCB947C-6994-4ACA-AF36-4B666124804E

Q26827467-22108EDA-FA0E-4D92-B738-5F3BDB850428

Q26827467-252C57A6-6B04-4AB3-BD3E-64C43C7C9433

P2888

Q26827467-DAE9E552-2578-4EE1-9269-D36D33506304

P304

Q26827467-5064956C-BBA7-4C6B-9628-0BD9D965B66C

P31

Q26827467-095BB5DE-3C07-44E8-9892-29D234B904FC

P3181

Q26827467-7946DF34-BF53-49D0-B792-0E56FCEE12AA

P356

Q26827467-CA838B29-B085-4683-A2BA-089177934D67

P407

Q26827467-3DF20F09-1759-4205-97FB-17B2EEB6426D

P433

Q26827467-04CE90D2-4F3B-4143-A5A0-4A45A9BC8DFD

P478

Q26827467-7785E31B-5105-47C6-B127-064FAB6206C5

P50

Q26827467-251F8074-ACFC-41EB-A875-F27499FDFBF7

Q26827467-FC6FA2F8-B4E9-4488-A543-63D6D87EF24C

P577

Q26827467-DB345D9D-8246-46E8-9EFC-9B36802DC895

P6179

Q26827467-C7B110DB-4FEA-4EB2-9204-825A43BA627C

P698

Q26827467-40C9E88B-C013-431F-9A74-C4663740CED7

P921

Q26827467-708980CD-09F5-4DA7-9D83-324811C01FF0

P932

Q26827467-C0554566-F8B6-48E8-808D-822A8F0E82DD

P3181

P356

S13311-012-0172-3

P1433

Neurotherapeutics

P1476

Role of immunosuppressive therapy for the treatment of multiple sclerosis

@en

P2093

Hadar Kolb

http://www.w3.org/2001/XMLSchema#string

James M Stankiewicz

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Azathioprine for multiple sclerosis

Cyclophosphamide therapy in pediatric multiple sclerosis

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety

Preserving ovarian function in patients receiving cyclophosphamide.

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

P2888

s13311-012-0172-3

P304

77-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

470178

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S13311-012-0172-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Howard L. Weiner

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047001447

http://www.w3.org/2001/XMLSchema#string

P698

23271506

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3557368

http://www.w3.org/2001/XMLSchema#string